Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

National Cancer Institute Awards Two Lung Cancer CTC Development Contracts to Cynvenio Biosystems, Inc.

Published: Tuesday, February 07, 2012
Last Updated: Tuesday, February 07, 2012
Bookmark and Share
Company also announces additional equity investment of $2.0 million.

Cynvenio Biosystems, Inc. announced that the National Cancer Institute (NCI) awarded two Small Business Innovative Research (SBIR) contracts to develop novel lung cancer tests based on the isolation of mutation-bearing Circulating Tumor Cells (CTCs) from whole blood. The NCI awarded Phase I funding of $195,000 for each contract, and Cynvenio will be eligible to apply for Phase II funding of $1.5 million (for each contract) when the Phase I objectives are successfully achieved. Cynvenio's core technology was independently verified against clinical patient samples in 2011. The company also announced that it has received an additional $1.2 million from existing shareholders as part of a fully committed $2.0 million financing authorized by its board of directors.

For the first contract, Cynvenio will use the funding from the SBIR and its investors to develop a Liquid Biopsy(TM) blood test, and a companion diagnostic device that isolates CTCs from the peripheral blood of lung cancer patients in order to identify the DNA mutations associated with each individual's disease. Improvement of treatment outcomes for cancer patients with solid tissue tumors depends on the drug's ability to target the genetic mutations responsible for tumor growth. Currently, mutational analysis requires an invasive tissue biopsy, which is clinically impractical to perform repeatedly over time for longitudinal studies. As an alternative, extracting CTCs - cancer cells released into the bloodstream by the primary tumor - for molecular analysis offers an attractive strategy for genotyping patient-specific tumors and mutations.

For the second contract Cynvenio will use the funding from the SBIR and its investors to develop a CTC-based test to measure resistance to drugs in lung cancer patients. The evolving understanding of cancer indicates that every tumor has distinct characteristics driven by the molecular pathology of the disease. Predicted by this heterogeneity, targeted therapeutic agents are much more successful than a "one size fits all" approach. Currently, there are no tools to analyze resistance in solid tissue tumor cells other than a traditional biopsy. This limitation typically precludes testing for molecular markers that emerge during treatment. Cynvenio's goal is to develop and characterize a CTC-based molecular drug resistance test and demonstrate application in clinical samples. 15-20% of non-small cell lung cancers are driven by activating mutations in the epidermal growth factor receptor (EGFR), a mutation that can be very effectively treated with EGFR inhibitors such as gefitinib and erlotinib. Resistance to these drugs arises universally, caused half of the time by a T790M mutation. Currently, resistance is determined medically by demonstrating tumor progression. As an alternative approach, extracting the small number of CTCs released into the bloodstream for detection of the emergence of the T790M mutation offers a strategy for genotyping patient-specific tumor cells in real time. This will produce a fundamentally enabling technology for predictive cancer tests in personalized medicine.

"We are extremely pleased the NCI has awarded this funding which will allow Cynvenio and our clinical collaborators to accelerate our validation programs aimed at harnessing the DNA of mutation-bearing Circulating Tumor Cells in lung cancer patients," said Andre de Fusco, Cynvenio's CEO. "The NCI awards reflect a growing recognition that CTCs are central to the longitudinal testing of cancer patients and the implementation of personalized medicine models. We look forward to addressing all solid tissue tumor disease models in the future as we secure incremental funding for the LiquidBiopsy(TM) program."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Elevated Bladder Cancer Risk in New England and Arsenic in Drinking Water From Private Wells
Researchers have found that drinking water from private wells, may have contributed to the elevated risk of bladder cancer in northern new England.
Tuesday, May 03, 2016
Near-Atomic Resolution of Protein Structure Holds Promise for Drug Discovery
A new study shows that it is possible to use an imaging technique called cryo-electron microscopy to view the architecture of a metabolic enzyme bound to a drug that blocks its activity.
Friday, May 08, 2015
2011 Biospecimen Research Network (BRN) Symposium
The National Cancer Institute's (NCI) Biospecimen Research Network Symposium, "Advancing Cancer Research Through Biospecimen Science," will be held March 28-29, 2011, at the Bethesda North Marriott Hotel & Conference Center in Bethesda, MD
Friday, January 07, 2011
NCI Announces Plans to Reinvigorate Clinical Trials
The National Cancer Institute (NCI) has announced major changes to be made in the long-established Clinical Trials Cooperative Group Program that conducts many of the nationwide trials of new cancer therapies.
Friday, December 24, 2010
National Cancer Institute Awards Nearly $4M to University of new Mexico Cancer Center
The awards support cancer nanotechnology partnership with Sandia Labs.
Wednesday, November 10, 2010
Scientists Identify Markers on Human Breast Cancer Cells Linked to Development of a Form of Breast Cancer
The scientists named these human cells with tumor-forming ability in mice, xenograft-initiating cells, or XIC.
Friday, May 21, 2010
Expression of Proteins Linked to Poor Outcome in Women with Ovarian Cancer
The study led by NCI scientists may provide targets for the development of novel therapies for ovarian cancer.
Wednesday, April 21, 2010
Antibodies Against Abnormal Glycoproteins Identified as Possible Biomarkers for Cancer Detection
Scientists have found that cancer patients produce antibodies that target abnormal glycoproteins made by their tumors.
Thursday, February 04, 2010
The Cancer Genome Atlas Identifies Distinct Subtypes of Deadly Brain Cancer
According to study the most common form of malignant brain cancer in adults appears to be four distinct molecular subtypes.
Thursday, January 21, 2010
Diet May Protect Against Gene Changes in Smokers
A new study finds that leafy green vegetables, folate, and multivitamins could serve as protective factors against lung cancer in smokers.
Thursday, January 14, 2010
Gene Mutations Reveal Potential new Targets for Treating a Type of Non-Hodgkin's Lymphoma
Findings provide insight into a mechanism that cancer cells may use to survive.
Tuesday, January 12, 2010
Gene Mutations Reveal Potential new Targets for Treating a Type of Non-Hodgkin's Lymphoma
Findings provide insight into a mechanism that cancer cells may use to survive.
Friday, January 08, 2010
Drug for Multiple Myeloma Demonstrated to Extend Disease-Free Survival
Patients receiving lenalidomide following a blood stem cell transplant had their cancer kept in check longer than placebo receiving patients.
Thursday, December 24, 2009
Gene's Position in the Nucleus Can be Used to Distinguish Cancerous from Normal Breast Tissue
Researchers have identified several genes whose spatial position inside the cell nucleus is altered in invasive breast cancer.
Wednesday, December 09, 2009
Centralized Review Process Markedly Expedites Approval of Cancer Clinical Trials
CIRB for cancer clinical trials, which was created by the National Cancer Institute, expedites the time from concept to completion of crucial investigational research.
Thursday, November 05, 2009
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Implementation Science Approaches to Reduce Mother-to-Child HIV Transmission
The NIH study will investigate best practices to ease major disease burden in Sub-Saharan Africa.
Tough New Hydrogel Hybrid Doesn’t Dry Out
Water-based material could be used to make artificial skin, longer-lasting contact lenses.
New CAR T Cell Therapy Using Double Target Aimed at Solid Tumors
Researchers at Penn University have described how antibody, carbohydrate combination could apply to range of cancer types.
Lasers Carve the Path to Tissue Engineering
A new technique, developed at EPFL, combines microfluidics and lasers to guide cells in 3D space, overcoming major limitations to tissue engineering.
Link Between Canned Food, BPA Exposure Revealed
New Stanford research resolves the debate on the link between canned food and exposure to the hormone-disrupting chemical known as Bisphenol A, or BPA.
Portable Test Rapidly Detects Zika
To better diagnose and track the disease, scientists are now reporting a new $2 test that in the lab can accurately detect low levels of the virus in saliva.
Erasing Unpleasant Memories with a Genetic Switch
Researchers from KU Leuven and the Leibniz Institute for Neurobiology have managed to erase unpleasant memories in mice using a 'genetic switch'.
Unidentified Spectra Detector
New algorithm clusters over 250 million spectra for analysis, such that millions of unidentified peptide sequences can be recognised.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!